486 related articles for article (PubMed ID: 22205141)
1. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients.
Schwentner L; Wolters R; Wischnewsky M; Kreienberg R; Wöckel A
Breast; 2012 Apr; 21(2):171-7. PubMed ID: 21945313
[TBL] [Abstract][Full Text] [Related]
3. [Effects of guideline-compliant therapy on the survival of primary breast cancer patients with: results of a retrospective cohort study].
Wolters R; Wöckel A; Wischnewsky M; Kreienberg R
Z Evid Fortbild Qual Gesundhwes; 2011; 105(6):468-75. PubMed ID: 21843852
[TBL] [Abstract][Full Text] [Related]
4. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients.
Schwentner L; Van Ewijk R; Kurzeder C; Hoffmann I; König J; Kreienberg R; Blettner M; Wöckel A
Eur J Cancer; 2013 Feb; 49(3):553-63. PubMed ID: 22959469
[TBL] [Abstract][Full Text] [Related]
5. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients.
Wolters R; Wöckel A; Janni W; Novopashenny I; Ebner F; Kreienberg R; Wischnewsky M; Schwentner L;
Breast Cancer Res Treat; 2013 Dec; 142(3):579-90. PubMed ID: 24258258
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
7. Outcome of pure mucinous breast carcinoma compared to infiltrating ductal carcinoma: a population-based study from China.
Cao AY; He M; Liu ZB; Di GH; Wu J; Lu JS; Liu GY; Shen ZZ; Shao ZM
Ann Surg Oncol; 2012 Sep; 19(9):3019-27. PubMed ID: 22451233
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
10. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
[TBL] [Abstract][Full Text] [Related]
11. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
12. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
13. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
14. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
15. Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study.
Wöckel A; Varga D; Atassi Z; Kurzeder C; Wolters R; Wischnewsky M; Wulff C; Kreienberg R
Onkologie; 2010; 33(1-2):21-8. PubMed ID: 20164658
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial.
Wang J; Shi M; Ling R; Xia Y; Luo S; Fu X; Xiao F; Li J; Long X; Wang J; Hou Z; Chen Y; Zhou B; Xu M
Radiother Oncol; 2011 Aug; 100(2):200-4. PubMed ID: 21852010
[TBL] [Abstract][Full Text] [Related]
18. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A
Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.
Kennedy CR; Gao F; Margenthaler JA
J Surg Res; 2010 Sep; 163(1):52-7. PubMed ID: 20599225
[TBL] [Abstract][Full Text] [Related]
20. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?
Regierer AC; Wolters R; Kurzeder C; Wöckel A; Novopashenny I; Possinger K; Wischnewsky MB; Kreienberg R
Breast Cancer Res Treat; 2011 Jul; 128(1):273-81. PubMed ID: 21210206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
